Pilulka Lekarny a.s.

As of December 31, 2025, Pilulka Lekarny a.s. carries a market capitalization of 460.14M, placing it among publicly traded companies globally. Its enterprise value stands at 495.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Pilulka Lekarny a.s. has 2.71M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 0.53, and the price-to-book ratio stands at -3.44.

As of December 31, 2025, Pilulka Lekarny a.s. trades at an EV/EBITDA multiple of 25.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 495.73M versus a market cap of 460.14M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Pilulka Lekarny a.s. maintains a current ratio of 0.63, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -40.10, indicating conservative leverage, while an interest coverage ratio of 1.15 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -17.89, reflecting losses generated across the asset base. The company generates approximately 8.51M in revenue per employee across its workforce of 103.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.18 indicates how many times Pilulka Lekarny a.s. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Pilulka Lekarny a.s. recorded 107,000.00 in income tax expense. The company reported a pretax loss of -38.51M and -38.87M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pilulka Lekarny a.s.'s stock has declined approximately 48.68% over the past 52 weeks. The 50-day moving average sits at 111.46, while the 200-day moving average is 124.50.

Over the twelve months ended December 31, 2025, Pilulka Lekarny a.s. generated 876.42M in revenue and converted that into -38.87M in net income, yielding earnings per share of -14.27. EBITDA reached 19.52M, while operating income came in at -9.35M.

As of December 31, 2025, Pilulka Lekarny a.s. holds 15.64M in cash and equivalents against 55.30M in total debt, resulting in a net debt position of 39.66M. Total book value stands at -133.84M, with working capital of -83.51M providing operational flexibility.

Pilulka Lekarny a.s. produced -20.43M in operating cash flow over the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Pilulka Lekarny a.s. posted a gross margin of 4.45, reflecting its pricing power and cost economics. The operating margin of -1.07 and net profit margin of -4.43 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -4.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.49, meaning Pilulka Lekarny a.s. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pilulka Lekarny a.s.'s most recent stock split took place on May 23, 2023 with a 95:96 split ratio.

As of December 31, 2025, Pilulka Lekarny a.s. has an Altman Z-Score of 0.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.